Form 4: Avalo Therapeutics Director June Sherie Almenoff Increases Stake in Company

Director June Sherie Almenoff has increased her indirect holdings in Avalo Therapeutics through purchases of common stock via Meadowlark Management, LLC.

Summary

• June Sherie Almenoff, a director at Avalo Therapeutics, has reported purchasing 1,000 shares of common stock.
• The purchases were made indirectly through Meadowlark Management, LLC.
• 500 shares were bought on November 12, 2024, at a weighted average price of $12.499 per share.
• An additional 500 shares were bought on November 13, 2024, at $13 per share.
• Following these transactions, Ms. Almenoff's indirect holdings total 1,000 shares through Meadowlark Management, LLC.

Sentiment

Score: 6

Explanation: The document indicates a director is increasing their stake in the company, which is generally a positive sign. However, the transaction is relatively small and doesn't provide any broader context about the company's performance.

Positives

• A director is increasing their investment in the company, which can be seen as a positive signal.
• The purchases indicate confidence in the company's future prospects.

Risks

• The document does not provide any information about the company's overall financial health or future performance.
• The purchases are relatively small and may not be indicative of a broader trend.

Management Comments

• The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who trade their company's stock. It does not provide any specific information about the broader pharmaceutical industry.

Comparison to Industry Standards

• SEC Form 4 filings are a standard practice for publicly traded companies, and this filing is consistent with those standards.
• The transaction size is relatively small compared to large institutional trades, but is typical for individual director purchases.

Stakeholder Impact

• The increased stake by a director may be viewed positively by shareholders.

Key Dates

Keywords

Avalo Therapeutics, AVTX, June Sherie Almenoff, Director, Stock Purchase, Meadowlark Management, Beneficial Ownership, SEC Form 4